echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Kangfang Bio-PD-1/CTLA-4 was approved to start a global phase 3 clinical trial for the treatment of cervical cancer

    Kangfang Bio-PD-1/CTLA-4 was approved to start a global phase 3 clinical trial for the treatment of cervical cancer

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On April 28, Kangfang Bio-Bio announced that it has independently developed the world's first innovative tumor immunotherapy new drug Cadonilimab (PD-1/CTLA-4, R&D code: AK104) plus platinum-containing chemotherapy with or without bevacizumab It has been approved by the National Center for Drug Evaluation (CDE) to carry out a randomized, double-blind, placebo-controlled global phase III clinical study for the first-line treatment of persistent, recurrent or metastatic cervical cancer.

    This is China’s first first-line phase III clinical study of dual immunotherapy for cervical cancer.
    It is also approved by the U.
    S.
    Food and Drug Administration (FDA) as an orphan drug for the treatment of cervical cancer at the end of February.
    The product will be obtained in 2021.
    Another important development in China.

    There is currently no approved standard treatment for patients with cervical cancer who have failed chemotherapy with platinum-containing drugs.

    The objective response rate (ORR) of late-line chemotherapy is less than 10%, the progression-free survival time is short, the long-term chemotherapy is poorly tolerated, and the incidence of adverse reactions is high.
    Effective treatment drugs are needed to improve the efficacy and benefit of patients.

    Cadonilimab (AK104) is a new and potential next-generation backbone drug for PD-1/CTLA-4 bispecific tumor immunotherapy independently developed by Kangfang Bio.
    Its main indications include liver cancer, cervical cancer, lung cancer, gastric cancer, and esophageal squamous cell carcinoma.
    And nasopharyngeal carcinoma and so on.

    Preliminary data in the research of cervical cancer, gastric cancer and other tumors show that Cadonilimab is significantly less toxic than the combination therapy of PD-1 and CTLA-4, and has obvious safety and efficacy advantages.

    A few days ago, Kangfang Biosciences has successfully held this global phase III clinical research expert seminar.
    Many experts and scholars from world-renowned gynecological oncology research institutions including China, the United States, the European Union and Australia attended the meeting.

    End's previous selection of onlookers two sleep articles on the same day: The price of not sleeping well is not only "becoming stupid", but also making people "sad" Hot articles BMC: Fat burning "good helper"! Ingest this drink before exercise, and lose weight with half the effort.
    Cell: Upgraded CRISPR tool!
    It does not affect the DNA sequence, but it can switch genes on and off for a long time and reversibly.
    The real-world research results of 10 million people of domestically produced new crown vaccines have been released.
    The protective effect is 67%.
    Doctors of the Third Hospital of Rewen North Hospital reported unnecessary NGS tests for patients.
    Who is responsible for bad medical behavior?
    Medical immunotherapy| Biosimilars| Vaccines| Drug resistance| Drug targets| Healthy life| Pharmaceutical company news| Drug inventory| Pharmaceutical technology| Basic research on side effects of drugs/ Translational medicine leukemia| Lung cancer| Gastric cancer| Colorectal cancer| Liver cancer| Breast Cancer | Pancreatic Cancer | Cardiovascular Diseases | Neurodegenerative Diseases | Intestinal Microbial Medical Devices / Biotechnology In Vitro Diagnosis | Medical Devices | Bio-Nano | 3D Printing | Gene Testing | Single Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision medicine policy anti-cancer drugs | 4+7 volume procurement | Consumables | Filing system | Registrant system | Healthy China | New version of the basic drug catalog | AI medical devices | Telemedicine | Same stock market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | ChiNext | R & D Investment | Acquisitions | Market & Consumption
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.